FAVORABLE SAFETY PROFILE OF TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS: POOLED RESULTS FROM TWO PHASE 3 STUDIES

被引：0
|
作者：
Du Jardin, Kristian Gaarn [1 ]
Schlesinger, Todd [2 ]
Bhatia, Neal [3 ]
Berman, Brian [4 ]
Padulles, Laura [5 ]
Cutler, David [6 ]
Lebwohl, Mark [7 ]
机构：
[1] Almirall, Global Med Affairs, Barcelona, Spain
[2] Clin Res Ctr Carolinas, Charleston, SC USA
[3] Therapeut Clin Res, San Diego, CA USA
[4] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[5] Almirall, Barcelona, Spain
[6] Athenex Inc, Buffalo, NY USA
[7] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
PW15
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [1] TIRBANIBULIN 1% OINTMENT FOR ACTINIC KERATOSIS: POOLED DATA FROM TWO PHASE 3 STUDIES
    Du Jardin, Kristian Gaarn
    Blauvelt, Andrew
    Kempers, Steven
    Schlesinger, Todd
    Lain, Edward
    Padulles, Laura
    Wang, Hui
    Cutler, David
    Lebwohl, Mark
    Fang, Jane
    Kwan, Rudolf
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 52 - 52
  • [2] Tirbanibulin ointment 1% for actinic keratosis (AK): Pooled data from two phase 3 studies
    Blauvelt, Andrew
    Kempers, Steven
    Schleisinger, Todd
    Lain, Edward
    Wang, Hui
    Cutler, David
    Lebwohl, Mark
    Fang, Jane
    Kwan, Rudolf
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
  • [3] Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
    Blauvelt, Andrew
    Kempers, Steven
    Lain, Edward
    Schlesinger, Todd
    Tyring, Stephen
    Forman, Seth
    Ablon, Glynis
    Martin, George
    Wang, Hui
    Cutler, David L.
    Fang, Jane
    Kwan, Min-Fun R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (06): : 512 - 520
  • [4] Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results
    Kempers, Steven
    DuBois, Janet
    Forman, Seth
    Poon, Amy
    Cutler, Eva
    Wang, Hui
    Cutler, David
    Fang, Jane
    Kwan, Rudolf
    JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (11) : 1093 - 1100
  • [5] Early efficacy of tirbanibulin 1% ointment in actinic keratosis with good tolerability and sustained clearance: pooled phase III results
    Gupta, Girish
    Padulles, Laura
    Hernandez, Francisco
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 77 - 77
  • [6] Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study
    Li Pomi, Federica
    Vaccaro, Mario
    Pallio, Giovanni
    Rottura, Michelangelo
    Irrera, Natasha
    Borgia, Francesco
    MEDICINA-LITHUANIA, 2024, 60 (02):
  • [7] Improvement in pigmentation changes by Fitzpatrick skin type in actinic keratosis patients treated with tirbanibulin ointment 1%: pooled data from two Phase III studies
    Blauvelt, Andrew
    Lain, Edward
    Schleisinger, Todd
    Tomondy, Paul
    Salem, Raidah
    Padulles, Laura
    Hernandez, Francisco
    Falques, Meritxell
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB178 - AB178
  • [8] Phase 1 Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects With Actinic Keratosis
    Yavel, Regina
    Overcash, J. Scott
    Cutler, David
    Fang, Jane
    Zhi, Jay
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (03): : 397 - 405
  • [9] Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study
    Kirchberger, Michael Constantin
    Gfesser, Michael
    Erdmann, Michael
    Schliep, Stefan
    Berking, Carola
    Heppt, Markus Vincent
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (14)
  • [10] Tirbanibulin Ointment (1%) for the Treatment of actinic Keratoses (AK): pooled Data from two pivotal Phase III Clinical Trials
    Szeimies, R. M.
    Dirschka, T.
    Ocker, W. G.
    Melzer, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 43 - 43
12345